Eletriptan in migraine

References

• Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache41, 646–657 (2001).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Pascual J, Goadsby PJ et al. Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis. Headache41, 754–763 (2001).
   PubMed Web of Science ®Google Scholar
• ANN Practice Guidelines (2002).
   Google Scholar
• Dodick D, Lipton RB, Martin V et al. The Triptan Cardiovascular Safety Expert Panel. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache44, 414–425 (2004).
   PubMed Web of Science ®Google Scholar
• Hall GC, Brown MM, Mo J, MacRae KD. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology62, 563–568 (2004).
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology55, 754–762 (2000).
   PubMed Web of Science ®Google Scholar
• Pryse-Phillips WE, Dodick DW, Edmeads JG et al. Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society. CMAJ156, 1273–1287 (1997).
   PubMed Web of Science ®Google Scholar
• Diener HC, Brune K, Gerber WD, Gobel H, Pfaffenrath V. Treatment of migraine attacks and migraine prophylaxis: recommendations of the German Migraine and Headache Society. Med. Monatsschr. Pharm.21, 30–39 (1998).
   Google Scholar
• ANAES. Recommendations for clinical practice. Review of diagnosis and treatment of migraine in the adult and child October 2002. Professional recommendations and references: economic evaluation service. Rev. Neurol.159, S5–S15 (2003).
   Google Scholar
• Silberstein (1995).
   Google Scholar
• Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache39, S20–S26 (1999).
   Google Scholar
• Mathew NT, Hettiarachchi J, Alderman J. Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review. Headache43, 962–974 (2003).
   PubMed Web of Science ®Google Scholar
• Rance DJ, Clear N, Dallman L et al. Physicochemical comparison of eletriptan and other 5-HT1d- like agonists as a predictor of oral absorption potential. Headache37(5), 328 (1997).
   Google Scholar
• Evans DC, O’Connor D, Lake BG, Evers R, Allen C, Hargreaves R. Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab. Dispos.31, 861–869 (2003).
   PubMed Web of Science ®Google Scholar
• Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica31, 469–497 (2001).
   PubMed Web of Science ®Google Scholar
• Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R. Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H] eletriptan binding at human 5-HT1B and 5- HT1D receptors. Eur. J. Pharmacol.368, 259–268 (1999).
   PubMed Web of Science ®Google Scholar
• Pietrobon D, Striessnig J. Neurobiology of migraine. Nature Rev. Neurosci.4, 386–398 (2003).
   PubMed Web of Science ®Google Scholar
• Goldstein J, Massey K, Kirby S et al. Effect of high-dose intravenous eletriptan on coronary artery diameter. Cephalalgia24, 515–521 (2004).
   PubMed Web of Science ®Google Scholar
• MaassenVanDenBrink A, van den Broek RW, de Vries R, Bogers AJ, Avezaat CJ, Saxena PR. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology55, 1524–1530 (2000).
   PubMed Web of Science ®Google Scholar
• Nilsson T, Longmore J, Shaw D et al. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur. J. Pharmacol.372, 49–56 (1999).
   PubMed Web of Science ®Google Scholar
• Ishida T, Kawashima S, Hirata Ki et al. Serotonin-induced hypercontraction through 5-hydroxytryptamine 1B receptors in atherosclerotic rabbit coronary arteries. Circulation103, 1289–1295 (2001).
   PubMed Web of Science ®Google Scholar
• Carel I, Ghaleh B, Edouard A et al. Comparative effects of frovatriptan and sumatriptan on coronary and internal carotid vascular haemodynamics in conscious dogs. Br. J. Pharmacol.132, 1071–183 (2001).
   PubMed Web of Science ®Google Scholar
• Milton KA, Scott NR, Allen MJ et al. Pharmacokinetics, pharmacodynamics, and safety of the 5-HT(1B/1D) agonist eletriptan following intravenous and oral administration. J. Clin. Pharmacol.42, 528–539 (2002).
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet358, 1668–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Oldman AD, Smith LA, McQuay HJ, Moore RA. Pharmacological treatments for acute migraine: quantitative systematic review. Pain97, 247–257 (2002).
   PubMed Web of Science ®Google Scholar
• Diener HC, Ryan R, Sun W, Hettiarachchi J. The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg. Eur. J. Neurol.11, 125–134 (2004).
   PubMed Web of Science ®Google Scholar
• Mathew NT, Schoenen J, Winner P, Muirhead N, Sikes CR. Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache43, 214–222 (2003).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Ferrari MD, Olesen J et al. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Neurology54, 156–163 (2000).
   PubMed Web of Science ®Google Scholar
• Sandrini G, Farkkila M, Burgess G, Forster E, Haughie S. Eletriptan vs. sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. Neurology22(59), 1210–1217 (2002).
   Google Scholar
• Salonen R, Kori S, Scott A, Richardson MS. Encapsulated sumatriptan is not bioequivalent to commercial sumatriptan. Headache43, 923–928 (2003).
   PubMed Web of Science ®Google Scholar
• Schoenen J, Pascual J, Rasmussen S, Sun W, Sikes C, Hettiarachchi J. Patient preference for eletriptan 80 mg vs. subcutaneous sumatriptan 6 mg: results of a crossover study in patients who have recently used subcutaneous sumatriptan. Cephalalgia (2004) (In Press).
   Google Scholar
• Steiner TJ, Diener HC, MacGregor EA, Schoenen J, Muirheads N, Sikes CR. Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia23, 942–952 (2003).
   PubMed Web of Science ®Google Scholar
• Garcia-Ramos G, Hilliard B, Hettiarachchi J. Efficacy of eletriptan vs. naratriptan for the treatment of a single migraine attack: a multicenter, randomized, double-blind placebo-controlled trial. Presented at the 10th Annual Scientific Meeting of the International Association for the Study of Pain (IASP). San Diego, CA, USA (2002).
   Google Scholar
• Sikes C, Sunshine A, Olson NZ, Almas M, Tiseo P. Three outcome measures of meaningful relief of migraine: a comparative assessment using eletriptan and rizatriptan. Headache44, 268 (2000).
   Google Scholar
• DiamondML, Hettiarachchi J, Hilliard B, Sands G, Nett R. Effectiveness of eletriptan in acute migraine: primary care for excedrin nonresponders. Headache44, 209–216 (2004).
   PubMed Web of Science ®Google Scholar
• Farkkila M, Olesen J, Dahlof C et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia23, 463–471 (2003).
   PubMed Web of Science ®Google Scholar
• Goldstein J, Tiseo P, Denaro J, Sikes C. Efficacy of eletriptan in migraine patients reporting unsatisfactory response to rizatriptan. Poster presentation at the European Headache Federation annual meeting. (2004).
   Google Scholar
• Cady RK, Lipton RB, Hall C, Stewart WF, O’Quinn S, Gutterman D. Treatment of mild headache in disabled migraine sufferers: results of the Spectrum Study. Headache40, 792–797 (2000).
   PubMed Web of Science ®Google Scholar
• Cady RK, Sheftell F, Lipton RB et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin. Ther.22, 1035–1048 (2000).
   PubMed Web of Science ®Google Scholar
• Schoeneen J, Pascual J, Rasmussen S, Sun W, Sikes C, Hettiarachchi J. Patient preference for eletriptan 80 mg vs. subcutaneous sumatriptan 6 mg: results of a crossover study in patients who have recently used subcutaneous sumatriptan. Cephalalgia (2004) (In Press).
   Google Scholar
• Brandes JL. Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Cephalalgia (2004) (In Press).
   Google Scholar
• Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population- based study. Pain106, 81–89 (2003).
   PubMed Web of Science ®Google Scholar
• Bigal ME, Lipton RB, Tepper SJ, Rapoport AM, Sheftell FD. Primary chronic daily headache and its subtypes in adolescents and adults. Neurology63, 843–847 (2004).
   PubMed Web of Science ®Google Scholar
• Von Korff M, Stewart WF, Simon DJ, Lipton RB. Migraine and reduced work performance: a population-based diary study. Neurology50, 1741, 1745 (1998).
   PubMed Web of Science ®Google Scholar
• World Health Organization. World Health Report 2001, Figure 2.3: leading causes of years of life lived with disability (YLDs), in all ages and in 15–44 year olds, by sex, estimates for 2000. World Health Organization, Basel, Switzerland (2000).
   Google Scholar
• Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch. Intern. Med.159, 813–818 (1999)
   PubMed Web of Science ®Google Scholar
• Edmeads J, Mackell JA. The economic impact of migraine: an analysis of direct and indirect costs. Headache42, 501–509 (2002).
   PubMed Web of Science ®Google Scholar
• Wells N, Hettiarachchi J, Drummond M et al. A cost-effectiveness analysis of eletriptan 40 and 80 mg versus sumatriptan 50 and 100 mg in the acute treatment of migraine. Value Health6, 438–447 (2003).
   PubMed Web of Science ®Google Scholar
• Olesen J, Steiner TJ, Lipton RB. Reducing the Burden of Migraine. Oxford Univeristy Press, Oxford, UK (2003).
   Google Scholar
• Charlesworth B, Lipton RB, Stewart WF. A stratified approach to migraine management including zolmitriptan is clinically and economically superior to step care approaches: results from the DISC study. In: Reducing the Burden of Migraine. Olesen J, Steiner TJ, Lipton RB (Eds). Oxford Univeristy Press, Oxford, UK (2003).
   Google Scholar
• Belsey JD. Cost effectiveness of oral triptan therapy: a trans-national comparison based on a meta-analysis of randomised controlled trials. Curr. Med. Res. Opin.20, 659–669 (2004).
   PubMed Web of Science ®Google Scholar
• Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann. Neurol.55, 19–26 (2004).
   PubMed Web of Science ®Google Scholar
• Dodick DW, Martin VT, Smith T, Silberstein S. Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache44(Suppl. 1), S20–30 (2004).
   PubMedGoogle Scholar
• Tzourio C, Kittner SJ, Bousser MG, Alperovitch A. Migraine and stroke in young women. Cephalalgia20, 190–199 (2000).
   Google Scholar
• Tietjen GE. The relationship of migraine and stroke. Neuroepidemiology19, 13–19 (2000).
   PubMed Web of Science ®Google Scholar
• MassenVanDenBrink A, van den Broek RW, de Vries R, Bogers AJ, Avezaat CJ, Saxena PR. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology55, 1524–1530 (2000).
   Google Scholar
• Goadsby PJ, Hoskin KL. Differential effects of low dose CP122,288 and eletriptan on fos expression due to stimulation of the superior sagittal sinus in cat. Pain82, 15–22 (1999).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Hoskin KL, Storer RJ, Edvinsson L, Connor HE. Adenosine A1 receptor agonists inhibit trigeminovascular nociceptive transmission. Brain125(Pt 6), 1392–1401 (2002).
   PubMed Web of Science ®Google Scholar
• Roon KI, Olesen J, Diener HC et al. No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo- controlled clinical trials. Ann. Neurol.47, 238–241 (2000).
   PubMed Web of Science ®Google Scholar
• Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. Eur. Neurol.47, 99–107 (2002).
   PubMed Web of Science ®Google Scholar
• Chia YC, Lim SH, Wang SJ, Cheong YM, Denaro J, Hettiarachchi J. Efficacy of eletriptan in migraineurs with persistent poor response to nonsteroidal anti-inflammatory drugs.Headache43, 984–990 (2003).
   PubMed Web of Science ®Google Scholar